Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage completely [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share in one day [2] Case Details - The lawsuit seeks to recover losses for investors who were adversely affected by the alleged fraud [1] - The primary endpoint that was not met involved the change from baseline in mean daily OSC dose at week 48 [2] - Following the disappointing results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage [3][5] - The company's stock price plummeted by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [3][4] Summary by Sections Allegations - The complaint alleges that aTyr Pharma made overwhelmingly positive statements while concealing material adverse facts about Efzofitimod's efficacy [3] - The truth about the drug's performance was revealed on September 15, 2025, when the company announced that the EFZO-FIT study failed to meet its primary endpoint [3] Stock Performance - Following the announcement of the study results, aTyr's stock experienced a significant decline of 83.2% in just one day [3][4] Next Steps for Shareholders - Shareholders who purchased shares during the class period (January 16, 2025, to September 12, 2025) are encouraged to register for the class action by December 8, 2025 [4] - Registered shareholders will receive updates through a portfolio monitoring software [4] Law Firm Information - The Gross Law Firm is leading the class action and aims to protect investors' rights against deceit and fraud [5] - The firm emphasizes its commitment to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is reminding investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against aTyr [4]. - Investors who purchased aTyr securities between January 16, 2025, and September 12, 2025, are encouraged to discuss their legal rights [1][4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids completely [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [7]. Group 3: Financial Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma made overwhelmingly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The EFZO-FIT study did not meet its primary endpoint, specifically in the change from baseline in mean daily OSC dose at week 48, which was disclosed during an investor call on September 15, 2025 [1]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of aTyr during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by false or misleading statements that led to artificial inflation of stock prices [3].

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses from November 7, 2024, to September 12, 2025, due to misleading statements about the drug Efzofitimod [1][2][5]. Group 1: Class Action Details - The lawsuit, King v. aTyr Pharma Inc., seeks to represent all individuals and entities that acquired aTyr Pharma securities during the expanded class period [2]. - The previous class period began in January 2025, making this expansion significant for investors who purchased shares in late 2024 [2]. - The lead plaintiff deadline for the lawsuit is set for December 8, 2025 [5]. Group 2: Allegations Against aTyr Pharma - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated the drug Efzofitimod for patients with pulmonary sarcoidosis [6]. - Executives allegedly made overly positive statements about the study's design and the drug's efficacy, particularly regarding its ability to reduce steroid dependency [7]. - The lawsuit claims that aTyr concealed material adverse facts about the drug's effectiveness, leading to securities law violations [8]. Group 3: Market Reaction and Investigation - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a significant stock price drop from $6.03 to $1.02, an 83.2% decline [9][10]. - Hagens Berman is investigating whether aTyr misled investors regarding the drug's data and trial design while promoting its multi-billion-dollar market potential [11].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between January 16, 2025, and September 12, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that aTyr provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage completely [2] - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [2] - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request the Court to appoint them as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [1][3]. Summary by Sections Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company whose stock is traded on NASDAQ under the ticker ATYR [1]. Legal Investigation - The law firm Faruqi & Faruqi is encouraging investors who suffered losses from aTyr's securities between January 16, 2025, and September 12, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1]. Allegations - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [3]. - The EFZO-FIT study results indicated that efzofitimod did not significantly reduce the mean daily oral corticosteroid dose compared to placebo, with a reduction of only 2.79 mg for the drug versus 3.52 mg for placebo [4]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod compared to 40.2% on placebo [4]. Stock Performance - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4] Group 3: Case Allegations - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage completely, leading to investor damages when the truth was revealed [5]

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][2]. Group 1: Allegations and Study Results - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study's design and the drug's ability to allow patients to taper steroid usage completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action must submit their papers to the court by December 8, 2025, to serve as lead plaintiff [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless the case is won [5]. - The firm has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses due to misleading statements about the efficacy of its drug, Efzofitimod [1][2][4]. Group 1: Class Action Details - The new class action, King v. aTyr Pharma Inc., covers investors who acquired aTyr securities between November 7, 2024, and September 12, 2025, significantly extending the previous class period that began in January 2025 [2][4]. - The lawsuit alleges that aTyr and its executives made false statements regarding the drug's efficacy, leading to inflated stock prices [4][7]. Group 2: Drug Study and Allegations - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated Efzofitimod in patients with pulmonary sarcoidosis, aimed at reducing steroid dependency [5][6]. - Throughout the class period, aTyr executives reportedly expressed confidence in the study's design while allegedly concealing adverse facts about the drug's efficacy [6][7]. Group 3: Market Reaction - The truth about the drug's failure to meet its primary endpoint was revealed on September 15, 2025, leading to a drastic decline in aTyr's stock price from $6.03 to $1.02, a drop of 83.2% in one day [8][9]. - Following the announcement, aTyr indicated plans to engage with the FDA to determine a path forward after the setback [9]. Group 4: Investigation and Legal Actions - Hagens Berman, a prominent shareholders rights firm, is investigating whether aTyr misled investors about the drug's data and trial design, emphasizing its potential multi-billion-dollar market opportunity [10]. - The firm is urging affected investors to submit their losses and is seeking information from individuals who may assist in the investigation [3][11].